Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of JNJ-54861911 on QT/QTc Intervals in Healthy Subjects
NCT02152332Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in QT/QTc interval at Day 7. Started Jul 2014; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02152332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152332.